Chief Medical Officer
Developed 10 drugs which are currently in the market. For example, Enalapril (Vasotec) and Lisinopril (Prinivil/Zestril
Former CEO & President of Transcend Therapeutics Inc. Former Vice President of Medical Affairs for Vertex Pharmaceuticals Inc.
Former Executive Director at Novartis (formerly known as Ciba-Geigy Corporation. Former Senior Director at Merck/MSDRL Corporation.
He served as the Chairman of the Board of Directors of DNAPrint Genomics Inc.
Scientific Advisor for Athena Capital Partners Inc.
Richard H. Gabriel B.S., MBA
Former President of Calix Corporation, parent company to Pharm-Eco Laboratories Inc. From 2004 until 2008.
Chief Executive Officer and President for DNAPrint Genomics Inc.
Successfully completed formation of several private and public companies in the genetics, chemistry and pharmaceutical fields.
Has been a part of the development of four successful drugs that include: Amprenavir (VX-478), Emtricitabine (FTC), Altretamine (Hexalen), Zalcitabine (DDC).
A Supervisory Board member of Biofrontera AG (a public German company focused on dermatology).
Former CEO of DNAPrint genomics, Inc., which made history and earned international media attention by developing innovative consumer and forensic genomics products.
Executive manager of both private and public traded companies.
Founder and CEO of Okeanos Technologies.
Thought leader in the life sciences
Author of graduate level textbook on Human Genomics, dozens of conference presentations, publications and patents.
Led development and commercialization of over 45 diagnostic products including 22 oncology assays.
Research Director and Research Fellow at DuPont Medical Products and Dade Behring Diagnostics leading to over $200M in product sales.
Director of Project Management at DuPont Pharmaceuticals leading Personalized Medicine Team.
Director or Technology and Project Management at Diagnostic Oncology, CRO leading to over $150M in client product sales.
Founder and CEO of Biomarker Associates, Inc. supporting development and commercialization of new products at 8 technology startup companies and 3 major diagnostic companies
William Dalton, PhD, MD; former President & CEO, Moffitt Cancer Center, Founder & Director of Moffitt’s Personalized Medicine Institute and now President & CEO of M2Gen.
Said Sebti, PhD; Leader of the Drug Discovery program and Chair of the Department of Drug Discovery at Moffitt Cancer Center and Professor of Oncology and Molecular Medicine at the University of South Florida.
Richard Jove, PhD; Emeritus Director of the Beckman Institute & Oncology Division Director at City of Hope, Duarte CA and now President and Director, Vaccine & Gene Therapy Institute Port Saint Lucie, Florida
Jean-Yves Blay, MD, PhD Professor of Medicine Université Claude Bernard Lyon, France, Scientific Director of the Canceropole Lyon Rhône Alpes, Vice chairman of the EORTC Translational Research Advisory Committee Chairman Soft Tissue & Bone Sarcoma EORTC and French Sarcoma Group
David Frank, MD, PhD Associate Professor, Department of Medicine, Harvard Medical School. Associate Professor of Medicine, Medical Oncology, Dana Farber Cancer Center, Boston
Terry J Watnick MD. Associate Professor, Medicine, Director Baltimore Polycystic Kidney Disease Research and Clinical Core Center, Vice Chair, PKD Foundation Scientific Advisory Board.
Jing Zhou, MD, PhD, FASN, Director Center for Polycystic Kidney Disease Research, Harvard Medical School.